Search
Mabwell Biopharma Receives Approval for Phase II Clinical Trial of 9MW3811 Injection from NMPA
2025-09-01 /
Read about 0 minute
Author：小编
Mabwell Biopharma has independently developed 9MW3811, a humanized monoclonal antibody targeting human IL-11, which is classified as a Class 1 therapeutic biological product. The company has recently received approval from the National Medical Products Administration (NMPA) for initiating a Phase II clinical trial for the treatment of pathological scars. This milestone positions 9MW3811 as a potential first-in-class IL-11-targeted drug globally to enter the clinical stage specifically for pathological scar indications.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
